French market for ICDs (implantable cardioverter defibrillators) set to soar
This article was originally published in Clinica
Implantable cardioverter defibrillators (ICDs) should at last be appearing soon on the list of products used in French private sector hospitals that are reimbursed. After years of campaigning by industry, the national reimbursement pricing committee for medical devices sold in private hospitals has submitted its backing for reimbursement to the health ministry and a decision is expected imminently, along with the list of private clinics where these products may be implanted.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.